Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Shanghai Henlius Biotech and Organon announced successful results from the phase 3 clinical trial for HLX14, a biosimilar to Prolia and Xgeva. The trial met its primary endpoints, comparing efficacy, safety, and immunogenicity in postmenopausal women with osteoporosis. Henlius and Organon have an exclusive commercialization agreement for HLX14 in various markets, excluding China.
The positive outcome of Shanghai Henlius Biotech's phase 3 clinical trial for HLX14, a biosimilar to Prolia and Xgeva, is significant in the field of osteoporosis treatment. Biosimilars are medical products that are nearly identical to an original product manufactured by a different company and are rigorously tested to ensure their efficacy and safety match that of the original. The successful trial indicates a potential future reduction in treatment costs for osteoporosis, as biosimilars typically enter the market at a lower price point compared to their reference products.
The study's focus on bone mineral density (BMD) and serum type I collagen C-telopeptide (s-CTX) reflects critical markers for assessing osteoporosis treatment efficacy. BMD is a measure of bone strength and is used to diagnose osteoporosis and assess fracture risk. s-CTX is a biomarker for bone resorption, providing insight into the rate of bone turnover. The achievement of the primary endpoints suggests that HLX14 could be as effective as the reference drug in improving these markers, which is essential for regulatory approval and clinician acceptance.
Henlius Biotech's licensing agreement with Organon for the commercialization of HLX14 in major markets, excluding China, has strategic implications for both companies. For Organon, this agreement diversifies its portfolio and strengthens its presence in the biosimilar market, which is growing due to the increasing demand for cost-effective therapeutic options. The agreement with Henlius provides Organon with a competitive edge in the osteoporosis market, especially in regions like the United States, the European Union and Canada, where the aging population is driving demand for such treatments.
From an investor's perspective, the successful trial results may signal potential future revenue streams for both Henlius and Organon, contingent on regulatory approvals. The market for osteoporosis treatments is substantial, with a global prevalence that is expected to increase as the population ages. The entry of HLX14 could intensify competition, potentially impacting the market share of existing treatments, including the reference product, denosumab.
The economic implications of introducing a new biosimilar like HLX14 into the market are multifaceted. On one hand, it offers the potential for healthcare cost savings, particularly in countries with high medication expenditure. Biosimilars can lead to reduced prices through market competition, which is beneficial for healthcare systems, insurance companies and patients, especially those without comprehensive insurance coverage. On the other hand, the introduction of biosimilars can disrupt the market dynamics for the original manufacturers, leading to a potential decrease in their revenue and market share.
Long-term, the availability of biosimilars could encourage innovation as original biologic manufacturers may invest more in research and development to stay ahead of competition. For healthcare systems, the adoption of biosimilars like HLX14 could result in resource reallocation, allowing funds to be directed towards other areas of need. However, the uptake of biosimilars can be influenced by physician prescribing habits, patient acceptance and regulatory incentives or barriers, which may affect the projected economic benefits.
04/08/2024 - 06:00 AM
SHANGHAI, China & JERSEY CITY, N.J. --(BUSINESS WIRE)--
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX14. The agreement covers markets such as the United States , the European Union, and Canada . An exception to the agreement is China .
The randomized, double-blind, international multicenter, parallel-controlled phase 3 clinical study (NCT05352516 ) aimed to compare the efficacy, safety, tolerability, and immunogenicity of HLX14 with EU-sourced reference denosumab (Prolia® ) in postmenopausal women with osteoporosis at high risk for fracture. Eligible patients were randomised at a 1:1 ratio to receive subcutaneous injection of 60 mg of HLX14 or reference denosumab (Prolia® ) every six months. The primary efficacy endpoint of this study was the percentage change in bone mineral density (BMD) at the lumbar spine from baseline to Week 52 (D365) assessed by central imaging. The primary pharmacodynamic endpoint was the area under the effect–time curve for percentage change of serum type I collagen C-telopeptide (s-CTX) from baseline to Week 26 (D183) (AUEC0–26W ). The primary endpoints of this study were met.
Denosumab has been approved in various countries and regions under different trade names for a range of different indications such as for the treatment of osteoporosis in postmenopausal women at high risk for fracture, among others.
About Henlius
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China , 2 have been approved for marketing in overseas markets, 19 indications are approved worldwide, and 7 marketing applications have been accepted for review in China , the U.S. , and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centers and Shanghai -based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Facility and Songjiang First Plant, both certificated by China and the EU GMP.
Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China -developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe : Zercepac® ), the first China -developed mAb biosimilar approved both in China and Europe , HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.
To learn more about Henlius, visit www.henlius.com/en/ or connect with us on LinkedIn at https://www.linkedin.com/company/henlius/ .
About Organon
Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey .
For more information, visit http://www.organon.com and connect with us on LinkedIn , Instagram , X (formerly known as Twitter) and Facebook .
Cautionary Note Regarding Forward-Looking Statements
Some statements and disclosures in this press release are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about expectations regarding Organon’s license and supply agreement with Henlius. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning. These forward-looking statements are based on Organon’s current plans and expectations and are subject to a number of risks and uncertainties that could cause Organon’s plans and expectations, including actual results, to differ materially from the forward-looking statements.
Risks and uncertainties that may affect Organon’s future results include, but are not limited to, our inability to successfully commercialize products in our biosimilars portfolio, the performance, operations and regulatory compliance of Henlius and its suppliers, efficacy, safety, or other quality concerns with respect to marketed products, including market actions such as recalls, withdrawals, or declining sales; political and social pressures or regulatory developments, that adversely impact demand for, availability of, or patient access to Organon’s products; general economic factors, including recessionary pressures, interest rate and currency exchange rate fluctuations; general industry conditions and competition; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Organon’s ability to accurately predict its future financial results and performance; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of Organon’s patents and other protections for innovative products; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including Organon’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408963530/en/
Organon Media Contacts:
Karissa Peer
Hannah Silver
Organon Investor Contacts:
Jennifer Halchak
Alex Arzeno
Henlius Media Contacts
Bella Zhou
wenting_zhou@henlius.com
Janice Han
jiayi_han@henlius.com
Source: Organon & Co.
What is the ticker symbol for Organon?
The ticker symbol for Organon is OGN.
What are the primary endpoints of the phase 3 clinical trial for HLX14?
The primary endpoints of the phase 3 clinical trial for HLX14 were the percentage change in bone mineral density at the lumbar spine and the area under the effect–time curve for percentage change of serum type I collagen C-telopeptide.
What was the primary efficacy endpoint of the study?
The primary efficacy endpoint of the study was the percentage change in bone mineral density at the lumbar spine from baseline to Week 52.
What markets are covered by the license and supply agreement between Henlius and Organon?
The license and supply agreement between Henlius and Organon covers markets such as the United States, the European Union, and Canada.
What is the trade name for the reference denosumab used in the study?
The trade name for the reference denosumab used in the study is Prolia.
